Skip to main content

Sub menu

News and Community
About us

Search

Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

You are here

Home
Guidance and resources
Sponsors

Aspen Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (209)
ARTG (9)
Australian Public Assessment Report (AusPAR) (2)
Cancellation or suspension (2)
Prescription medicine registration (2)

Date

2024 (3)
2023 (2)
2022 (9)
2020 (11)
2019 (12)
2018 (11)
2017 (92)
2016 (35)
2015 (45)
2014 (2)
2011 (1)
2007 (1)

Results for "[search-keyword]"

Search

Sponsor content

224 result(s) found, displaying 1 to 10

Glucosamine 625 mg tablets Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
Aspen Pharma Pty Ltd - Ledermix Paste Cement & Hardeners Combination Package - Surgical procedure kit, dental, medicated, reusable Cancelled under Section 41GL(d) of the Act

7 June 2024

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
Aspen Pharma Pty Ltd - Ledermix Cement & Hardeners Refill Package - Surgical procedure kit, dental, medicated, reusable Cancelled under Section 41GL(d) of the Act

7 June 2024

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
LOGICIN DRY COUGH Pholcodine 1mg/mL oral liquid bottle (Cancellation from the ARTG under s.30(2)(a) of the Act)

29 March 2023

Cancellation or suspension

Regulatory action due to the product appearing to the Secretary that the quality, safety or efficacy of the goods was unacceptable, effective 29/03/2023
OPOD-P LIQUID (Aspen Pharma Pty Ltd)

20 March 2023

Prescription medicine registration

Active ingredients: Methadone hydrochloride.
APO-IPRATROPIUM ipratropium bromide anhydrous 500 microgram/mL inhalation ampoule Cancelled under Section 30(1)(c) of the Act

10 October 2022

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
APO-IPRATROPIUM ipratropium bromide anhydrous 250 microgram/mL inhalation ampoule Cancelled under Section 30(1)(c) of the Act

10 October 2022

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
BUTAMOL 5 salbutamol 5mg/2.5mL (as sulfate) inhalation ampoules Cancelled under Section 30(1)(c) of the Act

25 August 2022

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
BUTAMOL 2.5 salbutamol 2.5mg/2.5mL (as sulfate) inhalation ampoules Cancelled under Section 30(1)(c) of the Act

25 August 2022

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd
DEXMINE dexamfetamine sulfate 5 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

25 August 2022

Cancellation by sponsor

Requested by Aspen Pharma Pty Ltd

Pages

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

© Commonwealth of Australia